NEW YORK — In this video, David Eichenbaum, MD, director of research at Retina Vitreous Associates of Florida, discussed the latest developments surrounding geographic atrophy at OSN New York Retina.
Eichenbaum focused specifically on two products that have completed phase 3 studies, showing potential significance in regard to slowing geographic atrophy.
“After more than a decade of looking at complement modulation, it’s nice to see two programs showing that we’re actually moving the needle,” Eichenbaum said.